Investigation of Cas9 antibodies in the human eye

Preexisting immunity against Cas9 proteins in humans represents a safety risk for CRISPR–Cas9 technologies. However, it is unclear to what extent preexisting Cas9 immunity is relevant to the eye as it is targeted for early in vivo CRISPR–Cas9 clinical trials. While the eye lacks T-cells, it contains...

Descripción completa

Detalles Bibliográficos
Autores principales: Toral, Marcus A., Charlesworth, Carsten T., Ng, Benjamin, Chemudupati, Teja, Homma, Shota, Nakauchi, Hiromitsu, Bassuk, Alexander G., Porteus, Matthew H., Mahajan, Vinit B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881612/
https://www.ncbi.nlm.nih.gov/pubmed/35217666
http://dx.doi.org/10.1038/s41467-022-28674-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881612/
https://www.ncbi.nlm.nih.gov/pubmed/35217666
http://dx.doi.org/10.1038/s41467-022-28674-1

Ejemplares similares